Single Cell Multi-Omics Market Research Report Information By Product (Single-Cell Genomics, Single-Cell Proteomics, Single-Cell Metabolomics, Single-Cell Transcriptomics), By Application (Immunology, Cell Biology, Oncology, Neurology), By End-user (Hospital and Diagnostic Laboratories, Academic and Research Organizations, Pharmaceutical & Biotechnology Companies, Others) and By Region (North America, Europe, Asia-Pacific and Rest of the World) –Market Forecast Till 2032

Global Single Cell Multi-Omics Market Overview

Single Cell Multi-Omics Market Size was valued at USD 1.7 Billion in 2022. The Single Cell Multi-Omics market industry is projected to grow from USD 2 Billion in 2023 to USD 10.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.00% during the forecast period (2024 - 2032). The growing incidence of chronic illnesses, including cancer and infectious viral infections, along with the growing need for tailored healthcare are the key market drivers boosting the expansion of the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Single Cell Multi-Omics Market Trends

• Growing incidence of chronic illnesses, including cancer and infectious viral infections, is driving the market growth

Market CAGR for Single Cell Multi-Omics is being driven by the expandingnumber of chronic illnesses. Multiple types of molecules from individual cells are analyzed using single-cell multi-omics technology, which provides a deeper understanding of biology than can be gained from examining each molecular layer from different cells. The global single cell multi-omes market is expected to expand as a result of the rise in chronic illnesses, including cancer and viral infections. The benefit of single-cell technology is that it allows for the incorporation of omics-related data layers, which provide information essential to fully comprehending the biology of cellular heterogeneity.

Additionally, the market for single-cell omics is expanding due to a number of variables, one of which is the growing need for tailored therapy. Molecular analysis of individual cells can shed light on the underlying causes of disease and help develop more specialized and targeted treatments. Furthermore, the quick development of technology has reduced the cost and increased accessibility of single-cell omics. For example, the development of high throughput sequencing technology has allowed researchers to assess hundreds of single cells at once, generating a large amount of data very quickly. Additionally, because chronic diseases like cancer and neurological problems are becoming more common, there is a growing interest in understanding the molecular mechanisms behind these conditions.

The identification of biomarkers for illness diagnosis, prognosis and therapy response can be aided by single-cell omics. This may result in the creation of novel treatments and diagnostic tools. Therapeutic efficacy and toxicity can be evaluated, as well as potential therapeutic targets and pathways, with the aid of single-cell omics. This might result in the creation of safer and more effective medications. Food safety and traceability can be improved, as well as crop productivity and quality, with the aid of single-cell omics. More secure and sustainable food systems may result from this. The application of single-cell omics technologies presents ethical questions around data exploitation, informed permission and privacy. To guarantee ethical behavior and responsible use in the field, these concerns must be addressed.

For instance, according to estimates from arecent report, MOSAIC is a ground-breaking $50 million project that maps tumor architecture at single-cell resolution utilizing spatial omics technology. It has 100 times more tumor samples than any previous collection, with an astounding 7,000 covered. With the addition of 10x Genomics' state-of-the-art Visium technology for spatial transcriptomics and its industry-leading Chromium portfolio for single-cell analysis, MOSAIC will have unprecedented access to previously undiscovered insights into the interactions between immune cells and tumors.Thus,results in driving the Single Cell Multi-Omics market revenue.

Single Cell Multi-Omics Market Segment Insights

• Single Cell Multi-Omics Product Insights

The Single Cell Multi-Omics Market segmentation, based on Product, includes Single-Cell Genomics, Single-Cell Proteomics, Single-Cell Metabolomics and Single-Cell Transcriptomics. The single-cell genomics segment dominated the market. This is because it offers a resolution level that was previously unattainable, allowing for a more precise comprehension of cell function and improved understanding of disease causes. By making it possible to identify uncommon cell types and biomarkers that could be overlooked in bulk sequencing, they have the potential to completely transform personalized medicine and result in more accurate diagnosis and focused treatments.

• Single Cell Multi-OmicsApplication Insights

The Single Cell Multi-Omics Market segmentation, based on Application, includes Immunology, Cell Biology, Oncology and Neurology. The oncology category generated the most income. This is because this sector makes investments in drug development and research aimed at underserved patient populations and high-value indications. These goals should be highly marketable and yield a high return on investment. They should also make use of digital technologies, such machine learning and artificial intelligence, to improve patient monitoring and selection, optimize dosage and improve clinical trial design.

• Single Cell Multi-OmicsEnd-user Insights

The Single Cell Multi-Omics Market segmentation, based on End-user, includes Hospital and Diagnostic Laboratories, Academic and Research Organizations, Pharmaceutical & Biotechnology Companies and Others. The academic and research organizations generated the most income. They frequently serve as the impetus for the creation of novel single-cell omics technologies and techniques. They carry out fundamental studies to comprehend the fundamental biology of individual cells and develop novel instruments and methods for molecular analysis of these cells. Frequently, this research results in the creation of novel goods and services that biotech and pharmaceutical firms subsequently market.

Figure 1: Single Cell Multi-Omics Market, by End-user, 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Single Cell Multi-OmicsRegional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Single Cell Multi-Omics market area will dominate this market, owing to ahigh-throughput automated approach for producing protein therapeutic production cell lines will boost market growth in this region.

Further, the major countries examinedin the market reportare theUS, Germany, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan and Brazil.

Figure 2: SINGLE CELL MULTI-OMICSMARKET SHARE BY REGION 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

EuropeSingle Cell Multi-Omics market has the second-largest portion of the market due to the funding programs designed to foster creative research endeavors and partnerships. Further, the German Single Cell Multi-Omics market had the biggest market share and the UK Single Cell Multi-Omics market was the fastest growing market in the European region

The Asia-Pacific Single Cell Multi-Omics Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to the surge in demand for surgical masks due to the rising prevalence of chronic diseases including cancer and neurological disorders. Moreover, China’s Single Cell Multi-Omics market had the biggest market share and the Indian Single Cell Multi-Omics market was the fastest growing market in the Asia-Pacific region.

Single Cell Multi-OmicsKey Market Players& Competitive Insights

Leading market playersare putting a lot of money on R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developmentsinvolving the introduction of new products, contracts, M&A transactions, increased investment and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, Single Cell Multi-Omicsindustrymust provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the global Single Cell Multi-Omics industryto help customers and expand the market segment. In recent years, the Single Cell Multi-Omicsindustryhas provided some of the biggest benefits to medicine. Major players in the Single Cell Multi-Omics market, including CELLENION, PerkinElmer Inc., 10x Genomics, ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc., are engaging in research and development activities in an effort to boost market demand.

American company Bio-Rad Laboratories, Inc. develops and produces specialized technology products for the clinical diagnostics and life science research industries. The company was founded in Berkeley, California, in 1952 by married University of California, Berkeley students David and Alice Schwartz. Bio-Rad is a global company with operations centered in Hercules, California. In March 2023, Bio-Rad was given the iQ-Check kits that the company sells, approved by AOAC International and AFNOR for use with the CFX Opus Deep well Real-time PCR System.

Serving more than 155 countries, Illumina, Inc. is an American biotechnology firm with its headquarters located in San Diego, California.In Illumina was established on April 1, 1998, and it designs, produces and sells integrated solutions for the study of biological function and genetic diversity. Proteomics, genotyping and gene expression and sequencing are among the markets that the company supports with its range of goods and services. In September 2022, Illumina introduced NovaSeq X and NovaSeq X Plus. Compared to Illumina's earlier machines, which could only sequence 7,500 genomes annually, the NovaSeq X Plus can sequence 20,000 genomes annually and produce up to 16 Tb of data every run. Redeveloped reagents, dyes and polymerases are included in the series and can be delivered at room temperature.

Key Companies in the Single Cell Multi-Omicsmarket include

• CELLENION


• PerkinElmer Inc.


• 10x Genomics


• ANGLE plc


• Illumina, Inc.


• Bio-Rad Laboratories, Inc.

Single Cell Multi-Omics Industry Developments

October 2022: Innovation life science reagent and device firms Takara Bio USA, Inc. and BioExcel Diagnostic tools are developing and verifying a high-level, comprehensive technique for diagnosing infectious diseases based on syndromic markers. A fully owned subsidiary of Takara Bio Inc. is Takara Bio USA, Inc.

September 2022: QIAGEN and Neuron23 Inc., the first biotechnology company devoted to creating precision drugs for based on genetic neurological and immunological disorders, declared the signing of an agreement to develop a partner screening for Neuron23's brain penetrant, blocker for Parkinson's disease.

March 2023: Bio-Rad was given the iQ-Check kits that the company sells are approved by AOAC International and AFNOR for use with the CFX Opus Deep well Real-time PCR System.

Single Cell Multi-Omics Market Segmentation

Single Cell Multi-Omics Product Outlook

• Single-Cell Genomics


• Single-Cell Proteomics


• Single-Cell Metabolomics


• Single-Cell Transcriptomics

Single Cell Multi-Omics Application Outlook

• Immunology


• Cell Biology


• Oncology


• Neurology

Single Cell Multi-Omics End-user Outlook

• Hospital and Diagnostic Laboratories


• Academic and Research Organizations


• Pharmaceutical & Biotechnology Companies


• Others

Single Cell Multi-Omics Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  •  Japan
  
  
  •  India
  
  
  •  Australia
  
  
  •  South Korea
  
  
  • Australia
  
  
  •  Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Attribute/Metric	Details
Market Size2022	USD 1.7 Billion
Market Size 2023	USD 2 Billion
Market Size2032	USD 10.2 Billion
Compound Annual Growth Rate (CAGR)	22.00% (2024-2032)
Base Year	2023
Market Forecast Period	2024-2032
Historical Data	2019-2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors and Trends
Segments Covered	Product, Application, End-user and Region
Geographies Covered	North America, Europe, Asia-Pacific and the Rest of the World
Countries Covered	The US, Germany, France, UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan and Brazil
Key Companies Profiled	CELLENION, PerkinElmer Inc., 10x Genomics, ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc.
Key Market Opportunities	·         Growing need for tailored healthcare
Key Market Dynamics	·         Growing incidence of chronic illnesses, including cancer and infectious viral infections